Latest Pioglitazone Stories

A new study, published Sunday in the New England Journal of Medicine (NEJM), reveals that a combination treatment may be the best way to treat type 2 diabetes in children and adolescents. In an April 29 press release, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the division of the National Institutes of Health (NIH) which funded the study, stated that a combination of the medications metformin and rosiglitazone was more effective in treating youngsters...

The Actos Resource Center is the Web’s largest source for information on Actos research, side effects and legal news. Visit http://www.ActosCancer.com (PRWEB) April 27, 2012 The Actos Resource Center, a consumer advocacy group, is alerting patients in the United States of an additional warning issued over the safety of Actos by Canada’s top drug regulatory agency. Health Canada issued a warning on April 19, 2012 that the diabetes drug Actos may cause an increased risk of bladder...

DEERFIELD, Ill. and OSAKA, Japan, April 25, 2012 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone. Recently, Takeda provided...

The Consumer Justice Foundation, a for-profit corporation whose Web site URL can be found at http://www.sideeffectsrx.com, is a team of professional consumer advocates who provide free informational online resources regarding the potential dangers of certain prescription medications. The CJF hereby alerts the public that Health Canada has issued a statement linking the use of Actos to an increased risk of bladder cancer and that the labeling on the packages of this drug will include a...

The Consumer Justice Foundation, a for-profit corporation whose Web site URL can be found at http://www.sideeffectsrx.com, is a team of professional consumer advocates who provide free online informational resources to consumers that relate to the potential dangers of certain prescription medications. The CJF hereby alerts the public of a recent order issued by the judge in an Actos whistleblower lawsuit that unseals the claim that alleges that Takeda Pharmaceutical, the manufacturer of...

Although the drug metformin is considered the gold standard in the management of type 2 diabetes, a study by a group of French researchers published in this week's PLoS Medicine suggests that the long-term benefits of this drug compared with the risks are not clearly established—an important finding given that currently, thousands of people around the world are regularly taking metformin to help control their blood sugar levels in the belief that it also has long-lasting health benefits....

The widely used diabetes medicine metformin can have protective effects on the heart, reveals a new study conducted at the Sahlgrenska Academy, at the University of Gothenburg, Sweden. Researchers at the University of Gothenburg's Sahlgrenska Academy have shown in a preliminary study in rats that one of the most common diabetes drugs, metformin, also has a protective effect on the heart. The study, carried out in collaboration with a research group from Naples and published in the...

The Consumer Justice Foundation, a for-profit corporation whose web site URL can be found at http://www.sideeffectsrx.com is staffed by a team of professional consumer advocates whose mission is to alert the public of the potential dangers of certain prescription drugs by way of free online information resources. The CJF hereby alerts the public of an Actos whistleblower lawsuit that alleges that Takeda Pharmaceuticals, the manufacturer of diabetes drub Actos, influenced reports of risks...

Metformin treatment seen to prevent growth of calcium deposits in coronary arteries Treatment with the common diabetes drug metformin appears to prevent progression of coronary atherosclerosis in patients infected with HIV. In a presentation today at the 19th Conference on Retroviruses and Opportunistic Infections, Massachusetts General Hospital (MGH) researchers reported that study participants receiving daily doses of metformin had essentially no progression of coronary artery...